You are here: Industry Insights > SLE

News List

Eisai Enters Joint Research Alliance to Create SLE Treatment contractpharma
July 14, 2020
Aims to create a Japan-originated therapeutic drug for systemic lupus erythematosus using Eisai’s new oral Toll-Like Receptor 7/8 inhibitor E6742.
Provention Announces Positive Data from Lupus Treatment Study americanpharmaceuticalreview
March 19, 2020
Provention Bio announced positive top-line results from the Phase 1b portion of the PREVAIL (PRV-3279 EVAluation In Lupus) study evaluating PRV-3279 in healthy volunteers.
Peripheral Nervous System Events Not Common in Lupus drugs
January 06, 2020
Peripheral nervous system (PNS) disease is a component of systemic lupus erythematosus (SLE) disease activity and has a significant negative impact on health-related quality of life, according to a study published in the January issue of Arthritis & Rheum
Anifrolumab Improves Response at 52 Weeks in Lupus drugs
December 23, 2019
For patients with systemic lupus erythematosus (SLE), anifrolumab is associated with improved response at 52 weeks versus placebo ...
Many Systemic Lupus Erythematosus Patients Use Opioids drugs
September 27, 2019
Patients with systemic lupus erythematosus (SLE) are more likely to use opioids than persons without SLE, and most SLE patients who use opioids do so for more than one year ...
AstraZeneca’s SLE drug performs well in Phase III trial pharmaceutical-technology
September 03, 2019
AstraZeneca has announced anifrolumab met the primary endpoint of the Phase III Tulip trial studying 373 systemic lupus erythematosus (SLE) patients.
FDA approves first treatment for pediatric patients with lupus worldpharmanews
April 28, 2019
FDA approves first treatment for pediatric patients with lupus.
FDA Grants Fast Track Designation to the Baricitinib Development Program americanpharmaceuticalreview
December 14, 2018
Eli Lilly and Company and Incyte announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to baricitinib......
Mixed data for Xencor’s SLE drug pharmatimes
October 11, 2018
Xencor’s experimental systemic lupus erythematosus (SLE) drug XmAb5871 has failed to hit its key target in a mid-stage study.
AZ’ lupus therapy fails to hit the mark pharmatimes
September 14, 2018
AstraZeneca’s experimental drug anifrolumab has failed to hit targets in a late stage trial in patients with lupus.

Previous page 1 2 3 Next page